News Release
OvaScience to Present at Leerink Global Healthcare Conference
A live audio webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at www.ovascience.com.
A replay of the webcast will be archived on the
About
Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment, OvaPrime treatment and OvaTure treatment. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to: the possibility that international IVF clinics that
we work with may determine not to provide or continue providing the
AUGMENT treatment, or to delay such treatment based on clinical
efficacy, safety or commercial, logistic, regulatory or other
reasons;the science underlying our treatments (including the AUGMENT,
OvaPrime and OvaTure treatments), which is unproven; our ability to
obtain regulatory approval or licenses where necessary for our
treatments; our ability to develop our treatments on the timelines we
expect, if at all; our ability to commercialize our treatments, on the
timelines we expect, if at all; as well as those risks more fully
discussed in the “Risk Factors” section of our most recently filed
Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The
forward-looking statements contained in this press release reflect our
current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160203006457/en/
Source:
OvaScience
Rebecca J. Peterson, 617-420-8736
rpeterson@ovascience.com